(Reuters) - Former top legal executives at large companies including Microsoft, Intel and Eli Lilly submitted a legal brief ...

UVA professor Dr. Christopher Kramer explains how a new Eli Lilly drug may cut a significant heart attack risk factor by 95%.

We recently published a list of Jim Cramer Nailed These 11 Stock Picks. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other stocks that Jim ...

Across Wall Street, 44 publicly traded companies were upgraded to an equivalent rating of "Buy" or "Neutral" on Tuesday.

Walgreens (WBA) stock is rising after the company reported better-than-expected second quarter earnings while preparing for ...

Novo Nordisk is preparing to launch its blockbuster obesity drug Wegovy (injectable semaglutide) in India later this year, the company told Business Today, setting the stage for a high-stakes battle ...

Eli Lilly (LLY) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the ...

Eli Lilly (LLY) stock gains as Goldman Sachs upgrades it to Buy from Neutral citing the company's leadership position in the ...

A large database study suggests that patients with primary dysautonomias face a significantly increased risk for seborrheic ...

In a report released today, Akash Tewari from Jefferies maintained a Buy rating on Pfizer (PFE – Research Report), with a price target of ...

India’s obesity crisis fuels a $2.6 bn drug race as pharma firms rush to launch affordable semaglutide generics, aiming to ...

Goldman Sachs upgraded Eli Lilly (LLY) to Buy from Neutral with a price target of $888, down from $892, after assuming coverage of the name.